Insider Buy ·Filed Sep 15, 2026

NAMS

NewAmsterdam Pharma Co N.V.
BULLISH
Impact 5/10
Horizonweeks Processed16d 14h ago SEC0001193125-26-391985
Insider cluster: 1 insiders, $227K total
Actionable Insight ▲ Bullish

The CEO's open-market buy is a modest bullish signal, but the dollar amount is small relative to market cap. Given the ticker's historical pattern of high-score reports underperforming, treat this as a modest positive signal rather than a strong catalyst. Monitor for additional insider buying or upcoming catalysts (e.g., Phase 3 data, regulatory updates) to confirm conviction.

DirectionBullish
Confidencemedium
Horizonweeks
Latest settled — T+5d
NAMS ▲ +10.21% at T+5d
LONG call ✓ call won +10.21% · α vs SPY +8.08% · entry $21.16 → $23.32
Next anchor: T+20d in 10d
Latest observation: T+12 +19.54% FF3 residual α
Entry anchored
Sep 14, 04:00 PM ET
via 1-min bar
T+1d
+0.09%
call +0.09% · α +0.54%
$21.18
settled 17d ago
T+5d
+10.21%
call +10.21% · α +8.08%
$23.32
settled 11d ago
T+20d
—
call — · α —
—
in 10d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

CEO Michael Davidson purchased $227K of NAMS stock on the open market at $22.65/share, a standalone conviction buy. This is a bullish signal from the highest-ranking insider, though the dollar amount is modest relative to the $2.5B market cap (~0.009%). The buy is not part of a 10b5-1 plan and comes amid strong analyst consensus (91% bullish). Historical calibration on this ticker shows prior high-score reports underperformed, warranting a tempered impact score.

Key Financial Metrics

Direction
buying
Total Value
$226.5K
Insiders
1

Key Facts

  • CEO Michael H. Davidson purchased 10,000 shares of NAMS at $22.65/share on 2026-09-14, totaling $227K.
  • The purchase is an open-market buy (SEC Form 4 code P), not a 10b5-1 plan or grant.
  • Market cap is $2.5B; the buy represents ~0.009% of market cap, below the 0.1% materiality threshold.
  • Analyst consensus is 91% bullish (9 Strong Buy, 12 Buy, 2 Hold).
  • Prior high-score reports on NAMS (score 7) had negative T+20 alpha (-6.07% and -9.60%), suggesting over-scoring risk.

Financial Impact

CEO purchased $227K of common stock at $22.65/share; no financial impact on company operations.

dilution

Risk Factors

  • The $227K purchase is only ~0.009% of market cap, which is below the 0.1% materiality threshold for insider buys.
  • Historical calibration shows prior bullish reports on NAMS (score 7) had negative T+20 alpha, suggesting the stock may not respond positively to insider signals.
  • A single insider buy, even from the CEO, has limited predictive power without corroborating cluster activity or corporate catalysts.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001193125-26-391985
4 reports for NAMS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NAMS — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Buy
BULLISH ★ 5/10
$21.16 $23.32▲ +10.21%▲ +8.08%$23.20 (+9.64%)
Aug 5, 2026
8w ago
8-K
BULLISH ★ 7/10
$27.42 $27.83▲ +1.50%▲ +1.14%$23.20 (−15.39%)
Jul 24, 2026
10w ago
8-K
BULLISH ★ 7/10
$29.64 $28.46▼ −3.98%▼ −4.35%$23.20 (−21.73%)
Apr 8, 2026
25w ago
Press Release
NEUTRAL ★ 5/10
$34.01 $34.01· 0.00%▼ −3.52%$23.20 (−31.78%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (64h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access